302 related articles for article (PubMed ID: 23542506)
21. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis.
Braun T; Zwerina J
Arthritis Res Ther; 2011 Jul; 13(4):235. PubMed ID: 21861862
[TBL] [Abstract][Full Text] [Related]
22. The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review.
Sakthiswary R; Das S
Curr Drug Targets; 2013 Dec; 14(13):1552-7. PubMed ID: 23848441
[TBL] [Abstract][Full Text] [Related]
23. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
24. The effect of biologic agents on bone homeostasis in chronic inflammatory rheumatic diseases.
Di Munno O; Ferro F
Clin Exp Rheumatol; 2019; 37(3):502-507. PubMed ID: 30557124
[TBL] [Abstract][Full Text] [Related]
25. The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches.
Gupta N; Kanwar N; Arora A; Khatri K; Kanwal A
Clin Rheumatol; 2024 May; 43(5):1421-1433. PubMed ID: 38499817
[TBL] [Abstract][Full Text] [Related]
26. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of Disease: the link between RANKL and arthritic bone disease.
Schett G; Hayer S; Zwerina J; Redlich K; Smolen JS
Nat Clin Pract Rheumatol; 2005 Nov; 1(1):47-54. PubMed ID: 16932627
[TBL] [Abstract][Full Text] [Related]
28. Bone effects of biologic drugs in rheumatoid arthritis.
Corrado A; Neve A; Maruotti N; Cantatore FP
Clin Dev Immunol; 2013; 2013():945945. PubMed ID: 23864880
[TBL] [Abstract][Full Text] [Related]
29. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.
Komano Y; Nanki T; Hayashida K; Taniguchi K; Miyasaka N
Arthritis Res Ther; 2006; 8(5):R152. PubMed ID: 16987426
[TBL] [Abstract][Full Text] [Related]
30. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
Strand V; Kavanaugh AF
Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
[TBL] [Abstract][Full Text] [Related]
31. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
Romas E
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
[TBL] [Abstract][Full Text] [Related]
32. [Effects of biologic therapies on systemic osteoporosis in patients with rheumatoid arthritis].
Kotake S; Yago T; Nanke Y
Nihon Rinsho; 2009 May; 67(5):996-1002. PubMed ID: 19432123
[TBL] [Abstract][Full Text] [Related]
33. Rheumatoid arthritis-associated bone erosions: evolving insights and promising therapeutic strategies.
Yan M; Su J; Li Y
Biosci Trends; 2020 Nov; 14(5):342-348. PubMed ID: 32908076
[TBL] [Abstract][Full Text] [Related]
34. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
35. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
36. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.
Sucur A; Jajic Z; Artukovic M; Matijasevic MI; Anic B; Flegar D; Markotic A; Kelava T; Ivcevic S; Kovacic N; Katavic V; Grcevic D
Arthritis Res Ther; 2017 Jun; 19(1):142. PubMed ID: 28619088
[TBL] [Abstract][Full Text] [Related]
37. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
[TBL] [Abstract][Full Text] [Related]
38. Rheumatoid Arthritis in the View of Osteoimmunology.
Auréal M; Machuca-Gayet I; Coury F
Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33396412
[TBL] [Abstract][Full Text] [Related]
39. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
[TBL] [Abstract][Full Text] [Related]
40. IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis.
Park MK; Her YM; Cho ML; Oh HJ; Park EM; Kwok SK; Ju JH; Park KS; Min DS; Kim HY; Park SH
Immunol Lett; 2011 Sep; 139(1-2):42-51. PubMed ID: 21620893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
